Atorvia researches the role of proteins in kidney failure to develop preventative and therapeutic solutions. The company utilizes unique insights into the human proteome and advanced AI models to engineer novel therapeutics. This work aims to address treatment gaps for millions of patients suffering from kidney failure and associated long-term health complications.
Funding
$5.9K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Kidney failure affects millions, often requiring dialysis and leading to complications like heart disease and diabetes, yet effective treatment options remain limited. Current diagnostic methods may not detect early structural changes in stressed kidney cells, hindering timely intervention.
Solution
Atorvia is developing engineered peptide therapeutics designed to inhibit protein-protein interactions that lead to cell death in kidney failure. By targeting structural changes in stressed kidney cells, Atorvia's research aims to create new diagnostic and therapeutic strategies for kidney disease. Their novel peptide therapeutic is designed to address kidney failure, offering a potential treatment option for patients who currently lack alternatives. This approach seeks to prevent the need for dialysis and reduce the long-term health complications associated with kidney failure.
Target Audience
The primary target audience includes patients at risk of or suffering from kidney failure, as well as healthcare providers and researchers focused on kidney disease treatment and diagnostics.
Features
- Engineered peptide therapeutics targeting protein-protein interactions
- Focus on inhibiting cell death pathways in kidney cells
- Research-driven approach to identify structural changes in stressed cells
- Development of novel diagnostic strategies for early detection of kidney disease